Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: MRNA SNY NVAX DVAX INBX OCGN VXRT ADMA XERS HEPA

| Held by: AVUV VTI XBI IWM FNDA VXF IWN IBB DFAT VTWO

Index	RUT	P/E	8.45	EPS (ttm)	1.29	Insider Own	3.99%	Shs Outstand	52.70M	Perf Week	3.70%
Market Cap	574.05M	Forward P/E	-	EPS next Y	-	Insider Trans	-4.29%	Shs Float	50.42M	Perf Month	-10.19%
Enterprise Value	995.85M	PEG	-	EPS next Q	0.11	Inst Own	80.06%	Short Float	17.10%	Perf Quarter	0.46%
Income	75.90M	P/S	0.73	EPS this Y	991.30%	Inst Trans	4.48%	Short Ratio	10.15	Perf Half Y	24.35%
Sales	788.90M	P/B	0.99	EPS next Y	-	ROA	5.17%	Short Interest	8.62M	Perf YTD	-11.57%
Book/sh	11.05	P/C	2.30	EPS next 5Y	-	ROE	13.92%	52W High	14.06 -22.26%	Perf Year	15.42%
Cash/sh	4.74	P/FCF	410.03	EPS past 3/5Y	- -	ROIC	6.06%	52W Low	4.02 171.89%	Perf 3Y	-15.99%
Dividend Est.	-	EV/EBITDA	4.61	Sales past 3/5Y	-16.20% -1.15%	Gross Margin	46.03%	Volatility	6.53% 5.99%	Perf 5Y	-91.27%
Dividend TTM	-	EV/Sales	1.26	EPS Y/Y TTM	135.32%	Oper. Margin	14.70%	ATR (14)	0.62	Perf 10Y	-67.75%
Dividend Ex-Date	-	Quick Ratio	3.15	Sales Y/Y TTM	-29.91%	Profit Margin	9.62%	RSI (14)	42.09	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.76	EPS Q/Q	-56.11%	SMA20	-4.04%	Beta	2.37	Target Price	13.50
Payout	-	Debt/Eq	1.15	Sales Q/Q	-21.34%	SMA50	-8.43%	Rel Volume	0.29	Prev Close	11.03
Employees	900	LT Debt/Eq	1.15	Earnings	Oct 29 AMC	SMA200	22.01%	Avg Volume	849.09K	Price	10.93
IPO	Nov 15, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	983.33% 19.12%	Trades		Volume	66,616	Change	-0.91%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-30-24	Initiated	H.C. Wainwright	Buy	$15
Aug-22-24	Initiated	Rodman & Renshaw	Buy	$16
Mar-07-24	Upgrade	The Benchmark Company	Hold → Buy	$5
Nov-20-23	Resumed	JP Morgan	Underweight
Aug-29-23	Downgrade	The Benchmark Company	Buy → Hold
Apr-10-23	Upgrade	The Benchmark Company	Hold → Buy	$22
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$23 → $9
Nov-10-22	Downgrade	The Benchmark Company	Buy → Hold
Apr-29-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-20-22	Upgrade	The Benchmark Company	Hold → Buy	$77
Nov-08-21	Downgrade	The Benchmark Company	Buy → Hold
May-05-21	Downgrade	Argus	Buy → Hold
Apr-07-21	Initiated	The Benchmark Company	Buy	$150
Feb-24-21	Upgrade	Chardan Capital Markets	Neutral → Buy	$112
Feb-19-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$112
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight	$110
Sep-14-20	Resumed	JP Morgan	Neutral	$103
Jul-31-20	Reiterated	Chardan Capital Markets	Buy	$86 → $112
Sep-12-19	Initiated	Guggenheim	Buy
Sep-04-19	Upgrade	Wells Fargo	Market Perform → Outperform

Show Previous Ratings

Today 09:02AM	Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Jan-16-26 10:26AM	?Emergent BioSolutions (EBS) Receives a New Order from US Department of War (Insider Monkey)
07:46AM	Dirty Vaccines, Clean Cash: Emergent Ex-CEO Sued For Insider Trading (Benzinga)
06:24AM	Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading (BioPharma Dive)
Jan-15-26 01:08PM	NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading (The Wall Street Journal) -12.68%
08:00AM	Loading…
Jan-14-26 08:00AM	Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness (GlobeNewswire)
Jan-12-26 07:30AM	Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation (GlobeNewswire)
Jan-08-26 04:30PM	Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026 (GlobeNewswire)
08:00AM	Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa (GlobeNewswire)
Jan-07-26 07:59AM	Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 (GlobeNewswire) +5.70%
Dec-12-25 08:30AM	Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site (GlobeNewswire)
Dec-04-25 11:30AM	Qiagen (QGEN) Up 6.3% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-18-25 08:00AM	Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access (GlobeNewswire)
Nov-12-25 04:01PM	Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors (GlobeNewswire)
09:15AM	Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run? (Zacks)
08:55AM	Loading…
Nov-07-25 08:55AM	Looking for a Fast-paced Momentum Stock at a Bargain? Consider Emergent Biosolutions (EBS) (Zacks)
Oct-31-25 09:15AM	Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out? (Zacks)
Oct-30-25 04:08PM	Emergent BioSolutions Inc (EBS) Q3 2025 Earnings Call Highlights: Surpassing Revenue ... (GuruFocus.com) +36.60%
Oct-29-25 06:05PM	Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates (Zacks)
05:01PM	Emergent Biosolutions: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Emergent BioSolutions Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-28-25 08:00AM	Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness (GlobeNewswire)
Oct-08-25 07:45AM	Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025 (GlobeNewswire)
Sep-24-25 04:05PM	Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone (GlobeNewswire) +5.43%
02:05PM	3 Small-Cap Stocks to Watch After the Fed's Rate Cuts (MarketBeat)
Sep-19-25 08:34AM	Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner (GlobeNewswire)
Sep-15-25 08:35AM	Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain (GlobeNewswire)
Sep-09-25 12:10PM	US Government signs $56m smallpox/mpox vaccine order despite political disarray (Pharmaceutical Technology) +9.26%
07:30AM	Emergent BioSolutions Receives New Contract Modification for ACAM2000, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness (GlobeNewswire)
Sep-02-25 07:40AM	Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use (GlobeNewswire)
08:05AM	Loading…
Aug-29-25 08:05AM	Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day (GlobeNewswire)
Aug-27-25 08:01AM	Emergent BioSolutions to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-21-25 08:45AM	Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day (GlobeNewswire)
Aug-18-25 09:45AM	Big Rallies Brewing? 3 Analyst Favorites to Watch Closely (MarketBeat)
Aug-07-25 10:16AM	Influenza Vaccine Market Research Report 2025-2030 Featuring GSK, Abbott, Pfizer, AstraZeneca, Sanofi, Moderna, CSL, Emergent BioSolutions, BIKEN, Serum Institute of India, Sinovac, GC Biopharma (GlobeNewswire) +36.65%
Aug-06-25 05:22PM	Emergent Biosolutions: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Emergent BioSolutions Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-28-25 08:50AM	New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox (GlobeNewswire) -5.44%
08:50AM	Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives (GlobeNewswire)
Jul-15-25 07:30AM	Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire) -5.07%
Jul-08-25 04:45PM	Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts (GlobeNewswire) +6.70%
Jul-02-25 04:05PM	Emergent BioSolutions Expands NARCANDirect to Offer KLOXXADO (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate (GlobeNewswire) +7.73%
Jun-23-25 08:05AM	Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Bolster U.S. Biodefense Supply (GlobeNewswire)
Jun-20-25 08:13AM	Emergent BioSolutions Announces Addition to Russell 3000 Index (GlobeNewswire)
Jun-05-25 07:00AM	Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies (GlobeNewswire)
May-29-25 09:55AM	5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost (Zacks)
May-19-25 09:43AM	Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions (Zacks)
May-16-25 10:52AM	5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes (Zacks) +20.95%
May-14-25 07:32AM	Emergent BioSolutions to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-08-25 09:53AM	Q1 2025 Emergent BioSolutions Inc Earnings Call (Thomson Reuters StreetEvents) +34.18%
03:33AM	Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid ... (GuruFocus.com)
May-07-25 10:03PM	Emergent biosolutions reaffirms 2025 revenue guidance of $750M-$850M amid turnaround progress (Seeking Alpha)
10:01PM	Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	Emergent Biosolutions (EBS) Q1 Earnings Top Estimates (Zacks)
04:32PM	Emergent Biosolutions: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Emergent BioSolutions Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 05:07PM	Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health (GlobeNewswire) -7.87%
Apr-22-25 08:00AM	Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-10-25 09:52AM	Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last? (Zacks) -9.17%
Apr-09-25 08:45AM	JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks) +9.58%
Apr-08-25 12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha)
Mar-31-25 08:00AM	Emergent BioSolutions Announces Stock Repurchase Program (GlobeNewswire)
Mar-26-25 10:32AM	Emergent BioSolutions: I See Further Downside Ahead In This Value Trap (SeekingAlpha) -6.00%
Mar-20-25 04:30PM	Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 (GlobeNewswire)
08:30AM	Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues (SeekingAlpha)
08:06AM	Hikma announces Health Canada approval of KLOXXADO (naloxone HCl) Nasal Spray 8 mg (GlobeNewswire)
Mar-19-25 05:01PM	Emergent BioSolutions closes sale of Bayview facility to Syngene (SeekingAlpha)
04:30PM	Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International (GlobeNewswire)
Mar-18-25 08:00AM	Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products (GlobeNewswire)
Mar-13-25 11:00AM	Emergent signs financial investment agreement with Swiss Rockets (Pharmaceutical Technology) -10.41%
08:29AM	Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs (GlobeNewswire)
Mar-12-25 08:00AM	Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates (GlobeNewswire) +11.21%
Mar-10-25 09:14AM	Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International (GlobeNewswire)
Mar-04-25 06:59AM	Q4 2024 Emergent BioSolutions Inc Earnings Call (Thomson Reuters StreetEvents) -6.44%
02:45AM	Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript (Motley Fool)
02:05AM	Emergent BioSolutions Inc (EBS) Q4 2024 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
Mar-03-25 05:40PM	Emergent Biosolutions (EBS) Q4 Earnings Top Estimates (Zacks) -8.69%
04:45PM	Emergent Biosolutions: Q4 Earnings Snapshot (Associated Press Finance)
04:23PM	Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-18-25 08:55AM	Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 (GlobeNewswire) -14.20%
Feb-07-25 08:06AM	Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans (GlobeNewswire)
Jan-23-25 09:01AM	Emergent seeking to reverse fortunes and become a major overdose treatment player (Pharmaceutical Technology) +5.61%
Jan-16-25 08:00AM	Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA) (GlobeNewswire)
Jan-14-25 07:30AM	Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals (GlobeNewswire)
Jan-13-25 09:27AM	Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga (ansuvimab-zykl) Treatment for Ebola (GlobeNewswire)
Jan-08-25 07:45AM	Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 (GlobeNewswire)
07:30AM	Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax (Anthrax Vaccine Adsorbed) (GlobeNewswire)
Dec-30-24 05:26PM	Why Emergent BioSolutions Stock Blasted Higher Today (Motley Fool) +11.85%
Dec-16-24 08:00AM	Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) (GlobeNewswire)
Dec-03-24 06:47PM	Why Emergent BioSciences Stock Plummeted Today (Motley Fool) -5.59%
Nov-08-24 10:04AM	Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +7.00%
Nov-07-24 02:06PM	Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 (Benzinga) +19.57%
01:15AM	Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript (Motley Fool)
Nov-06-24 06:20PM	Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates (Zacks)
05:17PM	Emergent Biosolutions: Q3 Earnings Snapshot (Associated Press Finance)
04:49PM	Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa (GlobeNewswire)
04:05PM	Emergent BioSolutions Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-04-24 07:30AM	Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development (GlobeNewswire)
Oct-23-24 07:30AM	Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 (GlobeNewswire) -5.20%
Oct-11-24 12:33PM	Emergent BioSolutions Inc. (EBS): A Standout Among Best Performing Cheap Stocks in 2024 (Insider Monkey)

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company's Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LOUIS W SULLIVAN	Director	Jan 07 '26	Proposed Sale	13.99	25,748	360,142		Jan 07 04:27 PM
LOUIS W SULLIVAN	Director	Dec 22 '25	Proposed Sale	12.77	104,695	1,336,463		Dec 22 06:22 PM
Richard Ronald	Director	Dec 05 '25	Option Exercise	5.02	25,748	129,255	124,165	Dec 09 06:01 PM
Richard Ronald	Director	Dec 05 '25	Sale	11.97	21,984	263,077	98,417	Dec 09 06:01 PM
RONALD RICHARD	Director	Dec 05 '25	Proposed Sale	11.94	32,848	392,335		Dec 05 04:04 PM
DeGolyer Donald W	Director	Nov 10 '25	Sale	10.54	17,801	187,623	119,858	Nov 12 04:13 PM
Dayal Sujata Tyagi	Director	Nov 07 '25	Sale	10.00	8,552	85,520	88,980	Nov 10 04:09 PM
DONALD DEGOLYER	Director	Nov 10 '25	Proposed Sale	10.54	17,801	187,544		Nov 10 04:06 PM
SUJATA TYAGI DAYAL	Director	Nov 07 '25	Proposed Sale	10.00	8,552	85,520		Nov 07 04:02 PM
Glessner Coleen	EVP, Quality & Ethics, and CPL	Oct 07 '25	Sale	10.00	30,608	306,080	144,319	Oct 16 04:21 PM
COLEEN GLESSNER	Officer	Oct 07 '25	Proposed Sale	10.00	30,608	306,080		Oct 07 04:11 PM
Zoon Kathryn C	Director	Aug 15 '25	Sale	8.87	7,086	62,853	71,799	Aug 18 04:33 PM
KATHRYN ZOON	Director	Aug 15 '25	Proposed Sale	8.87	7,086	62,853		Aug 15 04:04 PM
DeGolyer Donald W	Director	Aug 12 '25	Sale	8.65	7,844	67,831	137,659	Aug 13 04:22 PM
DONALD DEGOLYER	Director	Aug 12 '25	Proposed Sale	8.65	7,844	67,831		Aug 12 04:06 PM
Katkin Keith	Director	May 23 '25	Sale	6.30	7,844	49,417	86,431	May 28 04:08 PM
KEITH KATKIN	Director	May 23 '25	Proposed Sale	6.30	7,844	49,409		May 23 04:04 PM
PAPA JOSEPH C	President and CEO	May 13 '25	Buy	5.83	60,000	349,800	342,500	May 15 04:02 PM
Fowler Neal Franklin	Director	Mar 12 '25	Sale	5.83	35,000	204,050	101,100	Mar 12 06:13 PM
Zoon Kathryn C	Director	Mar 12 '25	Sale	5.73	10,000	57,300	44,482	Mar 12 06:13 PM
Fowler Neal Franklin	Director	Mar 12 '25	Proposed Sale	5.83	35,000	204,005		Mar 12 05:34 PM
Zoon Kathryn C	Director	Mar 12 '25	Proposed Sale	5.73	10,000	57,300		Mar 12 05:23 PM

Open in Screener

SNDX

Syndax Pharmaceuticals Inc

Feb 12 • 11:02AM ET

21.38

-0.33 -1.54 %

Healthcare • Biotechnology • USA • NASD

SNDX Syndax Pharmaceuticals Inc daily Stock Chart

Peers: LLY MRK PFE JNJ BMY AMGN GILD REGN VRTX BMRN

| Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-3.62	Insider Own	3.01%	Shs Outstand	86.91M	Perf Week	6.08%
Market Cap	1.86B	Forward P/E	-	EPS next Y	-1.51	Insider Trans	-8.56%	Shs Float	84.30M	Perf Month	4.42%
Enterprise Value	1.77B	PEG	-	EPS next Q	-0.59	Inst Own	115.00%	Short Float	25.09%	Perf Quarter	20.56%
Income	-311.58M	P/S	16.65	EPS this Y	16.64%	Inst Trans	-4.62%	Short Ratio	12.91	Perf Half Y	58.93%
Sales	111.55M	P/B	16.09	EPS next Y	51.30%	ROA	-63.74%	Short Interest	21.15M	Perf YTD	1.74%
Book/sh	1.33	P/C	4.26	EPS next 5Y	-	ROE	-129.32%	52W High	22.73 -5.96%	Perf Year	43.85%
Cash/sh	5.02	P/FCF	-	EPS past 3/5Y	- -15.16%	ROIC	-71.20%	52W Low	8.58 149.13%	Perf 3Y	-15.91%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-44.66% 73.25%	Gross Margin	95.43%	Volatility	5.10% 5.18%	Perf 5Y	2.82%
Dividend TTM	-	EV/Sales	15.84	EPS Y/Y TTM	0.45%	Oper. Margin	-274.90%	ATR (14)	1.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.42	Sales Y/Y TTM	597.19%	Profit Margin	-279.31%	RSI (14)	54.59	Recom	1.07
Dividend Gr. 3/5Y	- -	Current Ratio	4.64	EPS Q/Q	28.82%	SMA20	2.54%	Beta	0.43	Target Price	39.38
Payout	-	Debt/Eq	2.99	Sales Q/Q	266.97%	SMA50	3.04%	Rel Volume	0.40	Prev Close	21.71
Employees	270	LT Debt/Eq	2.79	Earnings	Nov 03 AMC	SMA200	41.75%	Avg Volume	1.64M	Price	21.38
IPO	Mar 03, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.38% -4.49%	Trades		Volume	181,507	Change	-1.54%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-25	Resumed	H.C. Wainwright	Buy	$40
Sep-10-25	Resumed	Stifel	Buy	$44
Sep-04-25	Resumed	Guggenheim	Buy	$34
Aug-05-25	Reiterated	BTIG Research	Buy	$43 → $56
Jul-10-25	Initiated	Goldman	Buy	$18
Oct-24-24	Initiated	UBS	Buy	$37
Jun-28-24	Initiated	Jefferies	Buy	$37
Jan-31-24	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$36 → $23
Dec-22-23	Initiated	Mizuho	Buy	$45
Oct-25-23	Initiated	BofA Securities	Buy	$29
Oct-11-23	Initiated	Goldman	Buy	$30
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jul-11-23	Initiated	Guggenheim	Buy	$40
Apr-17-23	Resumed	BTIG Research	Buy	$34
Jan-31-23	Initiated	Stifel	Buy	$37
Jan-03-23	Initiated	JP Morgan	Overweight	$41
Jul-28-22	Resumed	B. Riley Securities	Buy	$31
Apr-11-22	Initiated	H.C. Wainwright	Buy	$31
Feb-15-22	Initiated	Goldman	Buy	$37
Jun-04-21	Resumed	Robert W. Baird	Outperform	$30 → $31

Show Previous Ratings

Feb-05-26 07:00AM	Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit (GlobeNewswire)
Feb-04-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-19-26 05:17PM	Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory (Insider Monkey)
Jan-12-26 07:00AM	Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-26 07:00AM	Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj (revumenib) Outside the U.S. (GlobeNewswire) +8.70%
07:00AM	Loading…
Jan-05-26 07:00AM	Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.07%
Dec-12-25 07:00AM	Revuforj (revumenib) Named Best New Drug at the Scrip Awards 2025 (GlobeNewswire)
Dec-08-25 06:50AM	Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum (GlobeNewswire)
Dec-03-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-01-25 07:00AM	Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-28-25 11:57AM	Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating (Insider Monkey)
Nov-16-25 10:07PM	JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains "Overweight" Rating (Insider Monkey)
Nov-11-25 01:07PM	Syndax Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily) +12.79%
Nov-07-25 10:53AM	PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised (Zacks)
Nov-06-25 11:23AM	ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
11:18AM	Loading…
11:18AM	TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up (Zacks)
Nov-05-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-25 06:03PM	Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) +11.56%
Nov-03-25 05:35PM	Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:29PM	Syndax: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
09:08AM	Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025 (GlobeNewswire)
09:08AM	Syndax Announces Compelling Revuforj (revumenib) and Niktimvo (axatilimab-csfr) Data Accepted for Presentation at ASH 2025 (GlobeNewswire)
Oct-31-25 09:25AM	Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-30-25 07:00AM	Syndax Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-28-25 10:00AM	Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-25 07:00AM	Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025 (GlobeNewswire)
Oct-24-25 01:58PM	Syndax Announces FDA Approval of Revuforj (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia (GlobeNewswire) -7.83%
Oct-04-25 04:54PM	Syndax's Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision (Insider Monkey)
Oct-03-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +5.13%
07:00AM	Loading…
Sep-19-25 07:00AM	Syndax's Revuforj (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia (GlobeNewswire)
Sep-16-25 01:13PM	Top Biotech Picks for 2025: BTIG Research Highlights Potential Winners (Investing.com) -5.05%
Sep-10-25 09:51AM	Synopsys downgraded, Oracle upgraded: Wall Street's top analyst calls (The Fly)
Sep-05-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +5.25%
Sep-01-25 09:55AM	Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade (Zacks)
Aug-28-25 01:59PM	Agilent Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise (Zacks)
Aug-26-25 07:00AM	Syndax Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-18-25 11:42PM	Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals (Insider Monkey)
Aug-17-25 11:41PM	BTIG Raises Syndax Pharmaceuticals (SNDX) PT to $56 Following Strong Q2 Revenue from Revuforj, Niktimvo (Insider Monkey)
Aug-14-25 09:55AM	Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect? (Zacks) +9.52%
Aug-13-25 01:15AM	FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals (Insider Monkey)
Aug-06-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
11:05AM	Citi ups Syndax target, opens upside catalyst watch (TipRanks)
Aug-04-25 05:15PM	Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +21.10%
04:11PM	Syndax: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-25 12:00PM	All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy (Zacks) +8.15%
10:00AM	Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline (Zacks)
09:55AM	Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know (Zacks)
Jul-28-25 07:00AM	Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 (GlobeNewswire)
Jul-09-25 12:55AM	Syndax's Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML (Insider Monkey) +5.60%
Jul-02-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-24-25 04:01PM	Syndax Announces FDA Priority Review of sNDA for Revuforj (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia (GlobeNewswire)
12:45PM	Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial (Insider Monkey)
Jun-13-25 12:10PM	Syndax reports publication of revumenib data from BEAT AML trial (TipRanks)
Jun-12-25 12:02PM	Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 (GlobeNewswire)
07:00AM	Syndax Presents New Revuforj (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 (GlobeNewswire)
Jun-05-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-25 07:00AM	Syndax Announces Participation in June Investor Conferences (GlobeNewswire)
May-14-25 09:30AM	Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj (revumenib) and Niktimvo (axatilimab-csfr) (GlobeNewswire) -8.93%
May-12-25 04:01PM	Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer (GlobeNewswire) -7.28%
May-09-25 09:55AM	Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? (Zacks)
May-08-25 07:00AM	Syndax Announces Participation in May Investor Conferences (GlobeNewswire) +10.21%
May-07-25 04:01PM	Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood (GlobeNewswire) -6.11%
May-06-25 01:13PM	Q1 2025 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -21.59%
03:06AM	Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-05-25 05:10PM	Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:08PM	Syndax: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-02-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
09:26AM	Syndax Pharmaceuticals Inc (SNDX) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Apr-28-25 07:00AM	Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025 (GlobeNewswire)
Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
Apr-04-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -9.71%
Apr-02-25 07:00AM	Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum (GlobeNewswire) +7.99%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-20-25 01:03PM	3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets (SeekingAlpha) +7.47%
Mar-05-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
10:00AM	Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ... (GuruFocus.com)
Mar-03-25 08:15AM	Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:13AM	Syndax: Q4 Earnings Snapshot (Associated Press Finance)
07:01AM	Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-25 07:07AM	Earnings To Watch: Syndax Pharmaceuticals Inc (SNDX) Reports Q4 2024 Result (GuruFocus.com)
Feb-25-25 07:00AM	Syndax Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-24-25 07:00AM	Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025 (GlobeNewswire)
Feb-04-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jan-30-25 07:00AM	Syndax Announces Participation in February Investor Conferences (PR Newswire)
Jan-15-25 05:34PM	Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes (PR Newswire)
Jan-13-25 07:00AM	Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-07-25 07:00AM	Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-03-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Dec-09-24 07:30AM	Syndax Announces Additional Positive Data for Revuforj (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial (PR Newswire) -8.52%
Dec-07-24 06:15PM	Syndax Presents Positive Revuforj (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting (PR Newswire)
Dec-04-24 01:32PM	Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-03-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Nov-27-24 07:00AM	Syndax Announces Participation at the Citi 2024 Global Healthcare Conference (PR Newswire)
Nov-18-24 07:12AM	Syndax secures FDA OK for new kind of leukemia drug (BioPharma Dive)
06:39AM	FDA approves Syndaxs Revuforj to treat leukaemia (Pharmaceutical Technology)
Nov-15-24 05:29PM	Syndax Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation (PR Newswire) -5.72%
Nov-14-24 08:00AM	Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon (PR Newswire)

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Metzger Michael A	Chief Executive Officer	Feb 09 '26	Sale	21.03	17,159	360,819	491,690	Feb 10 09:00 AM
Goldan Keith A.	Chief Financial Officer	Feb 09 '26	Sale	21.03	3,410	71,705	140,429	Feb 10 08:59 AM
Metzger Michael A	Officer	Feb 09 '26	Proposed Sale	21.03	17,159	360,826		Feb 09 03:57 PM
Goldan Keith A.	Officer	Feb 09 '26	Proposed Sale	21.03	3,410	71,707		Feb 09 03:42 PM
Metzger Michael A	Chief Executive Officer	Feb 06 '26	Sale	20.62	7,412	152,835	508,849	Feb 06 05:54 PM
Goldan Keith A.	Chief Financial Officer	Feb 06 '26	Sale	20.62	2,082	42,931	143,839	Feb 06 05:53 PM
Metzger Michael A	Officer	Feb 06 '26	Proposed Sale	20.62	7,412	152,836		Feb 06 03:47 PM
Goldan Keith A.	Officer	Feb 06 '26	Proposed Sale	20.62	2,082	42,931		Feb 06 03:43 PM
Metzger Michael A	Chief Executive Officer	Sep 08 '25	Option Exercise	10.90	157,307	1,714,646	455,968	Sep 08 06:45 PM
Metzger Michael A	Chief Executive Officer	Sep 08 '25	Sale	16.41	157,307	2,582,021	298,661	Sep 08 06:45 PM
MICHAEL METZGER	Director	Sep 08 '25	Proposed Sale	17.04	157,307	2,680,511		Sep 08 04:25 PM
Podlesak Dennis	Director	Aug 14 '25	Option Exercise	7.20	19,200	138,240	210,963	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 15 '25	Option Exercise	7.20	19,200	138,240	210,963	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 18 '25	Option Exercise	7.20	19,200	138,240	210,963	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 18 '25	Sale	15.84	19,200	304,170	191,763	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 15 '25	Sale	15.54	19,200	298,408	191,763	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 14 '25	Sale	14.19	19,200	272,521	191,763	Aug 18 05:02 PM
DENNIS G PODLESAK	Director	Aug 18 '25	Proposed Sale	15.74	14,400	226,656		Aug 18 04:36 PM
DENNIS G PODLESAK	Director	Aug 14 '25	Proposed Sale	13.45	43,200	581,040		Aug 14 04:26 PM
Goldan Keith A.	Chief Financial Officer	Jul 16 '25	Sale	9.29	1,296	12,033	92,450	Jul 18 04:30 PM
Metzger Michael A	Chief Executive Officer	Jul 16 '25	Sale	9.29	7,534	69,953	298,661	Jul 18 04:30 PM
Goldan Keith A.	Officer	Jul 16 '25	Proposed Sale	9.29	1,296	12,034		Jul 16 03:29 PM
Metzger Michael A	Officer	Jul 16 '25	Proposed Sale	9.29	7,534	69,955		Jul 16 03:21 PM
Gallagher Neil	Officer	Jul 10 '25	Proposed Sale	9.26	9,679	89,667		Jul 10 03:42 PM
Botwood Nicholas A.J.	Head of R&D, CMO	May 16 '25	Buy	8.99	11,765	105,826	35,165	May 19 04:03 PM
Huber Martin H. Jr.	Director	May 19 '25	Buy	8.99	5,000	44,950	79,000	May 19 04:02 PM
Katkin Keith	Director	May 19 '25	Buy	9.11	10,000	91,120	100,000	May 19 04:01 PM
Metzger Michael A	Chief Executive Officer	Mar 14 '25	Option Exercise	7.20	6,074	43,733	306,195	Mar 17 06:01 AM
Metzger Michael A	Chief Executive Officer	Mar 04 '25	Option Exercise	7.20	7,814	56,261	307,935	Mar 06 04:10 PM
Metzger Michael A	Chief Executive Officer	Mar 04 '25	Sale	15.05	7,814	117,564	300,121	Mar 06 04:10 PM
MICHAEL METZGER	Officer	Mar 04 '25	Proposed Sale	15.48	13,888	214,986		Mar 04 05:10 PM

EBS

Emergent Biosolutions Inc

SNDX

Syndax Pharmaceuticals Inc

Upgrade your FINVIZ experience